complementsystem

Cyclosporin A is a natural product and an active fungal metabolite, classified as a cyclic polypeptide immunosuppressant. It binds to cyclophilin and inhibits the activity of calcineurin (IC₅₀ = 7 nM) as well as CD11a/CD18 adhesion molecules. It is commonly used to induce uremia models.

Dexamethasone is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory, immunosuppressive, and apoptosis-inducing activities. It inhibits the production of inflammatory miRNA-155 exosomes in macrophages, significantly reduces inflammatory cytokine expression in neutrophils and monocytes, suppresses LPS-induced macrophage inflammation, and induces autophagy. It is commonly used to induce animal models of depression, muscle atrophy, and hypertension, and holds potential in COVID-19 research.

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

EG01377 2HCl is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) with a Kd value of 1.32 μM and an IC₅₀ value of 609 nM for both EG01377 2HCl against NRP1-a1 and NRP1-b1.EG01377 exhibits anti-angiogenic, antimigratory and antitumor activities.

BCX 1470 hydrochloride is a potent serine protease inhibitor with anti-inflammatory activity that inhibits the ester hydrolysis and haemolytic activity of factor D and C1s, and can be used to study oedema.

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

Iptacopan hydrochloride (LNP023 hydrochloride) is a small-molecule inhibitor and a complement factor B inhibitor (IC₅₀ = 10 nM, KD = 7.9 nM) with high selectivity, oral activity, and cell permeability, used for the treatment of complement-mediated diseases including paroxysmal nocturnal hemoglobinuria, IgA nephropathy, and C3 glomerulopathy.

3-Phenoxybenzaldehyde is a complement (classical pathway) inhibitor with IC₅₀ of 1388μM.

TLQP 21 acetate is a potent agonist of G-protein-coupled receptor complement-3a receptor 1 (C3aR1). The EC₅₀ values are 10.3 μM for mouse and 68.8 μM for human. TLQP 21 acetate is a VGF-derived peptide with endocrine and extraendocrine properties.

PMX 205 acetate is an antagonist of complement C5a receptor (C5aR; CD88).

SB290157 trifluoroacetate is a potent and selective antagonist of the C3a receptor, with an IC₅₀ of 200 nM.

W-54011 is a potent non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils (Ki: 2.2 nM). W-54011 inhibits C5a-induced intracellular Ca2+ mobilization, chemotaxis, and generation of ROS in human neutrophi

C1qProtein (Mouse) is a subunit of the complement system. It recognizes a variety of ligands and plays roles in maintaining immune system balance, promoting tissue repair, and defending against pathogens.

Leukadherin-1 is an allosteric activator of CD11b/CD18. Increasing CD11b/CD18-dependent cell adhesion to fibrinogen, Decreasing leukocyte motility and transendothelial migration; reduces inflammation.

C3a Receptor Agonist (C3a receptor agonist 1) binds the G protein-coupled C3a receptors (C3aRs) in the immune system complement pathway. Activation of C3aR prevents neutrophils from being mobilized in a model of intestinal ischemia-reperfusion injury. C3aRs are expressed on neural progenitor cells and immature neurons in adult mice. C3a stimulates differentiation of neural progenitor cells in vitro.

Complement factor D-IN-2 is an inhibitor that reduces the excessive activation of Complement factor D.

CP-447697, a lipophilic C5a receptor antagonist, exhibits an IC₅₀ of 31 nM. It is utilized in inflammation research.

CP-289 is a potent C5a receptor antagonist with IC₅₀ of 1 μM.

C3a 70-77 2TFA (Complement 3a (70-77)) is an octapeptide corresponding to the COOH terminus of C3a.

Sutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemolysis.

Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cutting of C5 and preventing the subsequent formation of membrane attack complex, which can be used to study extravascular hemolysis.

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.

Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.